

## Agents for treating cerebral tumors

### Domaines d'application

Neoplastic meningitis - Cerebral metastasis - Glioma

### Contexte

Tumoral origin of meningitis results from the extension to intra-ventricular spaces of primary brain tumors or from meningeal metastasis. Prognostic of patients with neoplastic meningitis due to solid tumors is poor (median survival  $\approx$  4 months), and treatments are lacking or insufficient. Clinical trials are increasing, searching for new antineoplastic treatments using immunotherapy. Despite these new studies, sufficient clinical responses are limited.

### Description de la Technologie

This new therapeutic protocol proposes to administer TLR9 agonist and antiangiogenic agent, in order to induce rejection of cancerous cells using immune system mechanisms and also to have an impact on tumor growth . This treatment allows to overcome the lack of effective therapy in tumor meningitis, in particular in glioma meningitis mechanisms.

### Stade de Développement

Pre-clinical trial in laboratory - New protocol has been tested on syngeneic glioma models (RG2 Rat Fischer) - Result is a significant longer inhibition of tumor growth ( $p < 0,01$ ) compared to each agent used separately.

Phase 1 trial started in 2007 (n=29),

### Propriété Intellectuelle

EP and US patents - WO2012160153